Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systematic vs symptom-driven PPI after POEM in achalasia
2022-500218-25-01Phase 4Authorised
- Sponsor
- CHU Nîmes
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lansoprazole in achalasia and gastroesophageal reflux disease (GERD) (2 arms), sponsored by CHU Nîmes. Primary endpoint: Presence of pathological acid reflux at 6 months (Lyon 2018 criteria). Planned start Feb 2023; status: authorised.
02
Drugs
lansoprazole
03
Conditions
achalasiagastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2022-500218-25-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500218-25-01.